title: Clinical outcomes, resource use, and costs at 1 year in patients with acute coronary syndrome undergoing PCI: results from the multinational APTOR registry.
abstract: BACKGROUND
  Limited prospectively collected data are available on the total outcomes, cost estimates, and quality of life associated with treatment of acute coronary syndrome (ACS) through 1 year in a nonclinical-trial setting, or on the impact of new clinical events by 1 year on resource utilization and costs.
  
  
  METHODS
  The Antiplatelet Therapy Observational Registry (APTOR) 12-month study followed 1,335 concurrently recruited ACS patients undergoing percutaneous coronary intervention (PCI) and treated with antiplatelet therapy from France, Spain, and the United Kingdom in a "real world" clinical setting. Data were collected on clinical events, resource utilization, quality of life, and cost estimates through 1-year follow-up.
  
  
  RESULTS
  By 1 year, 14.4% (95% CI 12.7-16.4%) of patients experienced a clinical event of death, MI, stroke, unstable angina, urgent target vessel revascularization, or acute heart failure. Costs by 1 year were higher among those who had a new clinical event (£8,988, 95% CI £7,848, £10,395) as compared with those with no events (£5,809, 95% CI £5,486, £6,161). This increased cost was due to higher postdischarge resource use costs. Using the EQ-5D assessment at 1 year, quality of life was directionally lower in those patients who had experienced a new clinical event.
  
  
  CONCLUSIONS
  The risk of experiencing a new clinical event during the year following an ACS, which was treated with PCI, remains high among European patients, with one-seventh of patients having a new event. These additional clinical outcomes reduce quality of life and increase health care expenditures, expanding the already high cost of treatment for ACS.
authors.affiliation: Barnet & Chase Farm NHS Trust, Barnet, UK. abakhai@tiscali.co.uk
authors.forename: Ameet
authors.initials: A
authors.lastname: Bakhai
authors.forename: Jean
authors.initials: J
authors.lastname: Ferrieres
authors.forename: Andres
authors.initials: A
authors.lastname: Iñiguez
authors.forename: Magali
authors.initials: M
authors.lastname: Sartral
authors.forename: Mark
authors.initials: M
authors.lastname: Belger
authors.forename: Claude
authors.initials: C
authors.lastname: Schmitt
authors.forename: Uwe
authors.initials: U
authors.lastname: Zeymer
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy / Q000191:economics / Q000453:epidemiology / Q000628:therapy; D006328:Cardiac Catheterization / Q000191:economics; D005260:Female; D005602:France / Q000453:epidemiology; D017048:Health Care Costs; D006296:Health Services / Q000191:economics* / Q000706:statistics & numerical data*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011446:Prospective Studies; D012042:Registries; D013030:Spain / Q000453:epidemiology; D016019:Survival Analysis; D016896:Treatment Outcome; D006113:United Kingdom / Q000453:epidemiology
chemical_list: D010975:Platelet Aggregation Inhibitors